CBG

Recent studies have spotlighted the anticancer capabilities of cannabinoids like delta-9 THC, CBD and CBG and their potential to inhibit tumor growth and improve palliative care.  Despite mounting experimental evidence supporting these cannabis compounds' effectiveness in various cancers, the...

Avicanna Inc. (OTC: AVCNF) biopharmaceutical company announced Thursday the successful export of its Aureus-branded cannabigerol (CBG) products to Denmark. This marks the 19th international market for Aureus-branded products and the 22nd market overall for Avicanna's product...

A recent clinical trial has identified potential therapeutic benefits of cannabigerol (CBG), a cannabinoid that has not been as widely studied as THC or CBD. The study, conducted by researchers at Washington State University (WSU) and the University of California, Los Angeles (UCLA), indicates...

Cannabinoid-focused biopharmaceutical company Avicanna Inc. (TSX:AVCN) (OTCQX:AVCNF) (FSE: 0NN) announced on Thursday that it has completed the commercial export of Aureus-branded purified cannabigerol (CBG) products into Singapore through its majority-owned subsidiary Santa Marta Golden Hemp. The...

Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) is launching Wildflower brand edibles crafted with minor cannabinoids in four flavors that provide a range of experiences to meet various consumer needs, including CBN, CBG and CBD, as well as full spectrum THC Live Rosin. Sweet Dreams...

This article was originally published on Askgrowers and appears here with permission. Marijuana lovers already know that cannabis contains THC and CBD. The percentage of these cannabinoids decides the weed characteristics. But in fact, there are many more cannabinoids definitions than just two....

How many potential benefits does the cannabis plant with its 550+ chemical compounds hold for our health? No one knows, but as scientists have increased opportunities to research it, each new study provides another piece of this large puzzle. This time, researchers at the...

This article was originally published in May 2022. Can cannabinoid content in the cannabis plant be manipulated? And if so, how much?   According to a new report, researchers at the lab of Prof. Alexander (Sasha) Vainstein at Hebrew University in Rehovot...

This article was originally published on Cannabis.net and appears here with permission. Cannabigerol (CBG) is quickly becoming one of the most popular cannabinoid products these days. More than just a buzzword, CBG exists in the hemp plant as a precursor to CBD as well as THC. Also...

This article was originally published on NisonCo and appears here with permission. Although we usually hear about tetrahydrocannabinol (THC) and cannabidiol (CBD) when it comes to cannabinoids, there are many more with promising therapeutic potential. Cannabinoids are compounds that are naturally...

Radicle Science will launch large-scale, blinded, placebo-controlled clinical trials on rare cannabinoids including THCV, CBN, CBG, and CBC, to study their effects on energy, focus, appetite, sleep disturbance, pain, stress, and anxiety. These unprecedented Radicle Discovery studies will involve...

Original publication date: November 9, 2020 4:30 pm Much of cannabis’ disruptive potential lies in the plant’s ability to produce cannabinoids like THC and CBD. When it comes to rare cannabinoids, however, a different approach might yield better results. Scientists have found...

Willow Biosciences Inc. (TSX: WLLW) (OTCQB: CANSF) released its third-quarter financial and operating results Monday, revealing it has ended the quarter in a strong financial position, with approximately $35.7 million in cash on hand. Q3 Financial Summary Net...

On Wednesday, the Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) announced the launch of what it is calling the first cannabis edible in Canada to contain THC and cultured cannabigerol (CBG) from fermentation in a sweet gummy for adult consumers. The product, dubbed SPINACH FEELZ...

Cannabinoid company Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) is amending its previous partnership agreement with Ginkgo Bioworks, Inc., a company involved in cell programming. The amendment allows Cronos to start commercializing products with cultured cannabinoids before...